Lazard Asset Management
CAPR icon

Lazard Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Lazard Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69
Closed – – 2325
2024
Q4 		$0 Hold
69
– – ﹤0.01% 2305
2024
Q3 		$1K Sell
69
-112
-62% -$554 ﹤0.01% 2130
2024
Q2 		$0 Sell
181
-2,512
-93% -$14K ﹤0.01% 2241
2024
Q1 		$17K Buy
+2,693
New +$13K ﹤0.01% 1852

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lazard Asset Management's CAPR Position: Q1 2025 in Review

Lazard Asset Management sold out of Capricor Therapeutics (CAPR) in Q1 2025, closing a stake of 69 shares.

Lazard Asset Management first reported a position in CAPR in Q1 2024 and held it in 4 quarters. The position peaked at $17K in Q1 2024. 120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

  • Lazard Asset Management reported no remaining Capricor Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 69 Capricor Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Capricor Therapeutics in Q1 2024 and held it in 4 quarters.
  • Lazard Asset Management's Capricor Therapeutics position peaked at $17K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.